Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A neoadjuvant study of sequential epirubicin + cyclophosphamide and paclitaxel +/- gemcitabine in the treatment of high risk early breast cancer with molecular profiling, proteomics and candidate gene analysis.

Trial Profile

A neoadjuvant study of sequential epirubicin + cyclophosphamide and paclitaxel +/- gemcitabine in the treatment of high risk early breast cancer with molecular profiling, proteomics and candidate gene analysis.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2015

At a glance

  • Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Cyclophosphamide; Epirubicin
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms CRUK-neo-tAnGo; Neo-tAnGo
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 18 Dec 2013 Results published in the Lancet Oncology.
    • 31 May 2012 Additional location (Wales) added as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top